BARCELONA, October 6 — Theriva Biologics’ stock ticker TOVX moved into focus this week after the company announced that results from its VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic cancer were published in Nature Medicine, marking a rare peer-reviewed milestone for an early-stage oncology candidate. The publication, released on September 30, 2026, detailed findings from a randomised trial testing VCN-01 — an oncolytic adenovirus engineered to express hyaluronidase — combined with standard gemcitabine and nab-paclitaxel chemotherapy versus chemotherapy alone in patients with metastatic pancreatic cancer.
Kaplan-Meier analysis showed improved overall survival, progression-free survival, and duration of response in the combination arm, according to the study titled ‘Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomised phase 2b trial.’ Manel Cascalló, PhD, General Director of Theriva Biologics S.L. and a co-author of the article, said the validation through rigorous peer review underscores the scientific rigor of the VIRAGE study and highlights potential for combining VCN-01 with existing therapies.
He noted the data suggest an immune-mediated mechanism of action alongside the virus’s stroma-degrading properties, based on timing of immune responses observed in the trial. Following End-of-Phase 2 feedback from both the U.S. Food and Drug Administration and the European Medicines Agency, Theriva launched VIRAGE2, a small Phase 2a study assessing the feasibility of more frequent, repeated dosing of VCN-01 with chemotherapy. The first patient in VIRAGE2 was treated in August 2026, with full enrollment expected during the second half of 2026.
Initial pharmacodynamic and safety data from VIRAGE2 are anticipated by the third quarter of 2027. These results will help shape the dosing regimen for VCN-01 should the company advance to a pivotal Phase 3 trial in metastatic pancreatic cancer.
In parallel, Theriva is working with the FDA to finalize the design of a potential Phase 2/3 study evaluating VCN-01 in children with retinoblastoma that has vitreous seeds and is refractory to current intravitreal chemotherapy. VCN-01 has received Rare Pediatric Disease designation from the FDA for this retinoblastoma indication. If approved by September 30, 2029, the therapy could make Theriva eligible for a Priority Review Voucher, a tool that can accelerate future regulatory reviews or be transferred to other sponsors.
No financial figures, stock prices, revenue projections, or market impact details were included in the announcement. The company remains listed on NYSE American under the ticker TOVX. Investors will note that the Nature Medicine publication provides independent validation of early clinical signals, a step that often precedes broader investor interest in biotech pipelines.
The bottom line is that Theriva has moved VCN-01 from preclinical promise into peer-reviewed clinical evidence, with next steps now defined by ongoing VIRAGE2 data and regulatory discussions. Looking ahead, the readout of initial VIRAGE2 results in Q3 2027 will be a key inflection point, potentially informing whether VCN-01 advances to larger trials in pancreatic cancer or retinoblastoma.
Until then, the focus remains on executing the current studies and aligning with agency guidance on trial design.
